Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 6/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22232921 | 1.00 | TTK (0.58) | TTKLRRK2PTK2KMT2ASYK | |
| SCHEMBL22232854 | 0.94 | TTK (0.56) | TTKLRRK2PTK2SYK | |
| SCHEMBL30199066 | 0.94 | TTK (0.56) | TTKLRRK2PTK2SYK | |
| SCHEMBL25107258 | 0.93 | TTK (0.53) | TTKLRRK2PTK2KMT2AMAP4K1 | |
| SCHEMBL30199317 | 0.93 | TTK (0.53) | TTKLRRK2PTK2KMT2AMAP4K1 | |
| SCHEMBL25107242 | 0.93 | TTK (0.53) | TTKLRRK2PTK2KMT2AMAP4K1 | |
| SCHEMBL30199057 | 0.93 | TTK (0.53) | TTKLRRK2PTK2KMT2AMAP4K1 | |
| SCHEMBL25107244 | 0.92 | LRRK2 (0.59) | TTKLRRK2PTK2MAP4K1ALDH1A1 | |
| SCHEMBL30198923 | 0.92 | LRRK2 (0.59) | TTKLRRK2PTK2MAP4K1ALDH1A1 | |
| SCHEMBL22232892 | 0.91 | TTK (0.55) | TTKLRRK2PTK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | LRRK2, BRCA1, PARK7 | TTK 109/4885LRRK2 1/4885PTK2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.